Results 1 to 10 of about 386,376 (300)
Clinical Ophthalmology, 2008 Tryfon G Rotsos1, Marilita M Moschos21Medical Retina Service, Moorfields Eye Hospital, London, UK; 2Department of Ophthalmology, University of Athens, GreeceAbstract: We review the epidemiology, pathophysiology, and etiology of cystoid macular edema (CME)
Tryfon G Rotsos, Marilita M Moschos
doaj +5 more sources
Frontiers in Medicine, 2023 Macular edema is the pathological accumulation of fluid in the central retina. It is a complication of many retinal diseases, including diabetic retinopathy, retinal vascular occlusions and uveitis, among others.
Cameron D. Haydinger +3 more
semanticscholar +4 more sources
Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
Journal of Ophthalmology, 2019 Branch retinal vein occlusion (BRVO) is a very common retinal vascular problem in patients with lifestyle-related diseases, such as hypertension and arteriosclerosis.
Hidetaka Noma +2 more
doaj +2 more sources
Current Treatments for Diabetic Macular Edema
International Journal of Molecular Sciences, 2023 Diabetic retinopathy is a major retinal disorder and a leading cause of blindness. Diabetic macular edema (DME) is an ocular complication in patients with diabetes, and it can impair vision significantly.
T. Tatsumi
semanticscholar +1 more source
Pharmaceutics, 2023 Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME)
L. Ferro Desideri +3 more
semanticscholar +1 more source
Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition
International Journal of Molecular Sciences, 2023 This paper describes the current literature on the molecular pathophysiology of interleukin-6 (IL-6) in the genesis of macular edema and on the outcomes with IL-6 inhibitors in the treatment of non-infectious macular edema.
Janine Yang, David Goldberg, L. Sobrin
semanticscholar +1 more source
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Cells, 2022 Diabetic retinopathy (DR), with increasing incidence, is the major cause of vision loss and blindness worldwide in working-age adults. Diabetic macular edema (DME) remains the main cause of vision impairment in diabetic patients, with its pathogenesis ...
Jingfa Zhang +6 more
semanticscholar +1 more source
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
New England Journal of Medicine, 2022 BACKGROUND In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is ...
Chirag D. Jhaveri +15 more
semanticscholar +1 more source
Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Current Diabetes Reports, 2021 Purpose of Review This review highlights indications and evidence on laser therapy in the management of diabetic retinopathy and diabetic macular edema.
Lesley A. Everett, Y. Paulus
semanticscholar +1 more source
Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema
International Journal of Molecular Sciences, 2021 Diabetic macular edema (DME) is a critical complication of diabetic retinopathy, a condition that arises from the breakdown of the blood–retinal barrier and the consequent increase in vascular permeability.
H. Noma, K. Yasuda, M. Shimura
semanticscholar +1 more source